Chemical Safety Practices Recommendations
Buprenorphine (Buprenex, Temgesic, Subutex)

**Exposure Hazards (1)**

- **Category 4**
  - Warning
  - Toxic

Harmful if injected, inhaled, or swallowed. Affects Central Nervous System. Overdose may result in respiratory depression and death. (2)

- **Category 2**
  - Warning
  - Toxic to Reproduction

Use/Abuse of Buprenorphine during pregnancy may lead to symptoms of opioid withdrawal in newborn infants. (3)

**Response to Exposure**

<table>
<thead>
<tr>
<th>Oral</th>
<th>Dermal</th>
<th>Inhalation</th>
<th>Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinse mouth; do not induce vomiting. Report to OHS.</td>
<td>Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS if irritation develops.</td>
<td>Leave area; go to clean air. Report to OHS if difficulty breathing occurs.</td>
<td>Report to OHS.</td>
</tr>
</tbody>
</table>

**Special Precautions**

- Buprenorphine is a Schedule III Opioid and may be used as a drug of abuse. (4)

**Personal Protective Equipment**

- Gloves (Latex or Nitrile)
- Skin Protection (Suit, Scrubs or Lab Coat)
- Eye Protection (Safety-glasses or Goggles)
- Closed-toe shoes

**Engineering Controls**

- Buprenorphine powder- Chemical Fume Hood. (5)

**Animal Handling**

- No special precautions.

**Bedding Disposal**

- No special precautions.

**Work Practices**

- Buprenorphine is a Schedule III Opioid- Procurement and use must be documented and access restricted to the pure drug. Follow LASP SOPs for preparation, handling, dosing, and disposal of Buprenorphine.

**References:**


Questions or concerns: Please contact EHS, Ted Witte, theodore.witte@nih.gov or 301-846-5860
Reviewed 12/10/2014  These recommendations are not final and may be updated.
Chemical Safety Practices Recommendations

**Buprenorphine (Buprenex, Temgesic, Subutex)**

Buprenorphine is a u-opioid receptor antagonist/partial agonist similar in function to Methadone. It possesses strong analgesic effects for 8-12 hours but continues to block the receptor after the analgesic effects have worn off. Because of this, it is now often used as an alternative to Methadone in the maintenance treatment of opioid dependence.

While some manufacturer MSDSs may warn of reproductive hazards due to exposure, numerous studies have explored the effects of maternal consumption of Buprenorphine during pregnancy. Children born to mothers taking Buprenorphine exhibit opioid dependence but this effect is extremely unlikely to be caused by occupational exposure if the CSPR is observed.

Respiratory depression and death are unlikely to occur unless extremely large doses are taken, or it is taken in combination with other drugs of abuse.

Questions or concerns: Please contact EHS, Ted Witte, theodore.witte@nih.gov or 301-846-5860
Reviewed 12/10/2014  These recommendations are not final and may be updated.